IMMX vs NEM · $640.7M cap vs P/E 14, rev $13.43B
Immix Biopharma Inc (IMMX) versus Newmont Goldcorp Corp (NEM) — a side-by-side from cached financials, not a winner call.
Immix Biopharma Inc (IMMX) is a biotechnology company listed on US.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
IMMX does not have a complete income-statement cache yet.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
IMMX currently screens at market cap $640.7M. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Not investment advice. Open the IMMX and NEM stock pages for the full models.
Not investment advice.